表 4.
152例免疫联合治疗NSCLC患者LIPI、iSEND免疫评分与PFS的关系
Relationship between LIPI, iSEND immune score and PFS in 152 NSCLC patients treated with combined immunotherapy
| Predictive models | Group | n | mPFS (mon) | 95%CI |
| LIPI | Good | 46 | 10.7 | 8.844-12.642 |
| Intermediate | 70 | 5.9 | 4.293-7.469 | |
| Poor | 36 | 4.0 | 2.497-8.016 | |
| iSEND | Good | 21 | 11.0 | 7.385-14.562 |
| Intermediate | 105 | 7.4 | 5.842-9.008 | |
| Poor | 26 | 3.4 | 2.593-4.175 | |
| Total | 152 | 6.6 | 5.251-8.016 | |